A NRF2 inhibitor selectively sensitizes KEAP1 mutant tumor cells to cisplatin and gefitinib by restoring NRF2-inhibitory function of KEAP1 mutants
Tahar Aboulkassim, Xiaohong Tian, Qiang Liu, Dinghong Qiu, Mark A. Hancock, Jian Wu, Gerald Batist
Abstract
-based biosensor system to detect the KEAP1/NRF2 interaction and classify KEAP1 mutations. This strategy would identify drug-resistant KEAP1 somatic mutations in clinical molecular profiling of tumors.
Topics & Concepts
KEAP1CisplatinMutantChemistryCancer researchBiologyCell biologyBiochemistryGeneticsTranscription factorGeneChemotherapyGenomics, phytochemicals, and oxidative stressCircular RNAs in diseasesHistone Deacetylase Inhibitors Research